Tags : Surface Oncology

Weekly Snapshot

PharmaShots Weekly Snapshots (Dec 14-18, 2020)

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada Published: Dec 17, 2020 | Tags: Authorization, Biosimilar, canada, health, Humira, Hyrimoz, Launch, receives, Sandoz Amgen’s Riabni (biosimilar, rituximab) Receives the US FDA’s Approval for Multiple Diseases Published: Dec 17, 2020 | Tags: Adult, Amgen, approval, Biosimilar, CLL, GPA, MPA, NHL, patients, receives, RIABNI, Rituxan, Rituximab, rituximab-arrx, […]Read More


GSK Signs an Exclusive License Agreement with Surface Oncology to

Shots: Surface Oncology to receive ~$85 M upfront and ~$730 M as milestones along with royalties on net sales of SRF813 GSK to get an exclusive right to develop and commercialize Surface Oncology’s preclinical program, SRF813 SRF813 is an IgG1 Ab targeting PVRIG (also k/a CD112), currently in IND-enabling studies with anticipated IND submission in […]Read More